Business Description
Akari Therapeutics PLC
NAICS : 325412
SIC : 2834
ISIN : US00972G1085
Description
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | -0.05 | |||||
Debt-to-EBITDA | N/A | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 32.9 | |||||
3-Year EPS without NRI Growth Rate | 45 | |||||
3-Year FCF Growth Rate | 32.1 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 42.82 | |||||
9-Day RSI | 34.18 | |||||
14-Day RSI | 30.65 | |||||
6-1 Month Momentum % | -47.23 | |||||
12-1 Month Momentum % | -49.23 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.95 | |||||
Quick Ratio | 0.95 | |||||
Cash Ratio | 0.84 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -51 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History |
---|
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | N/A | |||||
PE Ratio without NRI | N/A | |||||
EV-to-EBIT | -0.33 | |||||
EV-to-EBITDA | -0.33 | |||||
EV-to-FCF | -0.34 | |||||
Earnings Yield (Greenblatt) % | -303.03 | |||||
FCF Yield % | -175.05 |